GLS Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 11.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Gelesis Insider Trading History Chart

This chart shows the insider buying and selling history at Gelesis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gelesis Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/10/2023 08:00 PM ET

This chart shows the closing price history over time for GLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Gelesis Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2022Raju S KucherlapatiDirectorBuy92,000$0.45$41,400.00190,264View SEC Filing Icon  
11/18/2022Raju S KucherlapatiDirectorBuy8,000$0.39$3,120.0098,264View SEC Filing Icon  
6/15/2022Raju S KucherlapatiDirectorBuy24,625$1.95$48,018.7590,264View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Gelesis (NYSE:GLS)

16.71% of Gelesis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GLS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Gelesis Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2023Caz Investments LP100,000$29K0.1%N/A0.137%Search for SEC Filing on Google Icon
11/15/2022Northeast Financial Consultants Inc395,035$0.43M0.0%+1,480.1%0.544%Search for SEC Filing on Google Icon
10/31/2022Vitruvian Partners LLP1,876,106$2.03M0.4%N/A2.584%Search for SEC Filing on Google Icon
10/26/2022Allspring Global Investments Holdings LLC25,957$28K0.0%N/A0.036%Search for SEC Filing on Google Icon
5/12/2022Northeast Financial Consultants Inc35,000$0.16M0.0%N/A0.101%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Gelesis logo
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Read More on Gelesis

Today's Range

Now: N/A

50 Day Range

MA: $0.21
Low: $0.11
High: $0.33

52 Week Range

Now: N/A

Volume

185,100 shs

Average Volume

386,034 shs

Market Capitalization

$11.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Who are the company insiders with the largest holdings of Gelesis?

Gelesis' top insider shareholders include:
  1. Raju S Kucherlapati (Director)
Learn More about top insider investors at Gelesis.